AVP Antibody (G-1): sc-390702

AVP Antibody (G-1) is a mouse monoclonal IgG1 antibody that detects arginine-vasopressin (AVP) in mouse samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). AVP is a crucial neurohypophyseal hormone that plays a significant role in maintaining body fluid homeostasis and is also implicated as an autocrine growth factor in various cancers, including breast cancer. AVP is primarily located in the hypothalamus and is secreted into the bloodstream, where AVP regulates water retention and vascular resistance by acting on specific receptors, namely Vasopressin V1a and V2. AVP interaction with these receptors not only influences blood pressure and fluid balance but also has implications for myocardial function, as V1a receptor activation can adversely affect myocardial contractility and promote cell growth. Furthermore, AVP′s role in cancer progression is underscored by AVP′s ability to activate the ERK1/2 signaling pathway, which is associated with increased tumor growth. Additionally, AVP has been shown to have potential therapeutic applications in managing acute and chronic heart failure, as well as in migraine relief due to AVP′s antinociceptive properties. Anti-AVP antibody (G-1) is therefore an invaluable tool for researchers investigating the multifaceted roles of AVP in both physiological and pathological contexts.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

AVP Antibody (G-1) References:

1. Septal arginine vasopressin (AVP) receptor regulation in rats depleted of septal AVP following long-term castration.  |  Poulin, P. and Pittman, QJ. 1991. J Neurosci. 11: 1531-9. PMID: 2045876
2. Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH).  |  Gassanov, N., et al. 2011. Eur J Clin Pharmacol. 67: 333-346. PMID: 21327910
3. Arginine vasopressin (AVP) expressional changes in the hypothalamic paraventricular and supraoptic nuclei of stroke-prone spontaneously hypertensive rats.  |  Yi, SS., et al. 2012. Anat Cell Biol. 45: 114-20. PMID: 22822466
4. Arginine vasopressin-dependent and AVP-independent mechanisms of renal fluid absorption during thirsting despite glucocorticoid-mediated vasopressin suppression.  |  Ufer, F., et al. 2013. Clin Endocrinol (Oxf). 78: 431-7. PMID: 22882308
5. Assessment of obestatin and arginine vasopressin (AVP) levels in acute renal failure and acute heart failure.  |  Miao, XY., et al. 2017. Eur Rev Med Pharmacol Sci. 21: 3277-3281. PMID: 28770954
6. Arginine Vasopressin-Aquaporin-2 Pathway-Mediated Dehydration Effects of Electroacupuncture in Guinea Pig Model of AVP-Induced Eendolymphatic Hydrops.  |  Jiang, LY., et al. 2019. Chin J Integr Med. 25: 763-769. PMID: 29335859
7. Exploring immunoreactivity of TTF-1 and AVP in hypothalamic hamartoma.  |  Rao, S., et al. 2022. Clin Neuropathol. 41: 18-24. PMID: 34142952
8. New developments and concepts in the diagnosis and management of diabetes insipidus (AVP-deficiency and resistance).  |  Angelousi, A., et al. 2023. J Neuroendocrinol. 35: e13233. PMID: 36683321
9. Arginine or Hypertonic Saline-Stimulated Copeptin to Diagnose AVP Deficiency.  |  Refardt, J., et al. 2023. N Engl J Med. 389: 1877-1887. PMID: 37966286
10. Arginine vasopressin (AVP) treatment increases the expression of inhibitory immune checkpoint molecules in monocyte-derived dendritic cells.  |  Ghahramanipour, Z., et al. 2024. Immunol Res. 73: 6. PMID: 39661295

The preferred AVP antibody is AVP Antibody (E-8): sc-390723.